bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures and Tables from Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer
Authors: Dolan M. Eileen , El Charif Omar , Wheeler Heather E. , Gamazon Eric R. , Ardeshir-Rouhani-Fard Shirin , Monahan Patrick , Feldman Darren R. , Hamilton Robert J. , Vaughn David J. , Beard Clair J. , Fung Chunkit , Kim Jeri , Fossa Sophie D. , Hertz Daniel L , Mushiroda Taisei , Kubo Michiaki , Einhorn Lawrence H. , Cox Nancy J. , Travis Lois B.
Published: April 2023

Supplementary Figures and Tables for Clinical and Genome Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer Figure S1. Diagram of Data Collection Pipeline. Table S1. EORTC-CIPN20 questionnaire. Figure S2. Flow diagram of GWAS Quality Control Pipeline. Table S2. Additional Diagnosis and Treatment Characteristics of TCS cohort. Figure S3. Response frequencies for the EORTC-CIPN20 questionnaire from 680 patients. Figure S4. Principal Component Analysis (PCA) of EORTC-CIPN20 items. Figure S5. SNP-level GWAS. Table S3. Top 100 GWAS Results (p < 2.25 x 10-5) Table S4. Review of candidate gene studies implicating SNPs in cisplatin-induced neuropathy and their replication in the TCS study. Table S5. Review of previous GWAS of CIPN implicating SNPs and their replication in the TCS study. Table S6. Top PrediXcan results (P < 0.001).
Figure S1 from Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
Authors: Yang Yu Chi , Banuelos Carmen Adriana , Mawji Nasrin R. , Wang Jun , Kato Minoru , Haile Simon , McEwan Iain J. , Plymate Stephen , Sadar Marianne D.
Published: April 2023

Immunohistochemistry of representative sections of LNCaP95 xenografts stained for cleaved caspase-3. Scale bars (red) indicate 20 µm. % of caspase-3 positive cells were counted in xenograft sections of each treatment. At least 1000 cells per xenograft were counted. Total number of cells counted: 3287 (Control), 4238 (EPI-002), and 4262 (ENZA). Bar graphs are mean {plus minus} SEM with n = at least 3 different xenograft sections. One-way ANOVA was used for statistical analyses; *p < 0.05; **p < 0.01; ***p<0.001.
Supp Figure Legends from Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
Authors: Morrow Matthew P. , Kraynyak Kimberly A. , Sylvester Albert J. , Dallas Michael , Knoblock Dawson , Boyer Jean D. , Yan Jian , Vang Russell , Khan Amir S. , Humeau Laurent , Sardesai Niranjan Y. , Kim J. Joseph , Plotkin Stanley , Weiner David B. , Trimble Cornelia L. , Bagarazzi Mark L.
Published: April 2023

Legends
89Zr- and 124I-anti-CD20 immunoPET SI from ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo
Authors: Zettlitz Kirstin A. , Tavaré Richard , Knowles Scott M. , Steward Kristopher K. , Timmerman John M. , Wu Anna M.
Published: April 2023

Supplementary data Table S1. Ex vivo biodistribution (24 h p.i.) of antibody fragments in SCID mice bearing 38C13-huCD20, blocked or CD20-negative 38C13 subcutaneous allografts. Data are presented as mean (%ID/g) with standard deviation ({plus minus} SEM). Table S2. Ex vivo biodistribution (24 h p.i.) of GA101 cys-diabody and cys-minibody fragments in human CD20 transgenic mice (huCD20TM). Data are presented as mean (%ID/g) with standard deviation ({plus minus} SEM). Figure S1 Biochemical characterization. (A) SDS-PAGE analysis of purified rituximab-based cys-diabody (RxcDb, 52 kDa) and cys-minibody (RxcMb, 82 kDa) shows correctly assembled dimers under non-reducing conditions (NR) and monomeric fragments under reducing conditions. (B) Size exclusion chromatography of engineered antibody fragments in comparison to full-length rituximab IgG. Rx cMb eluted as a single peak corresponding to the expected molecular weight. Rx cDb eluted slightly later, corresponding to the 52 kDa dimer but also showed a smaller second peak of higher molecular weight. Figure S2. (A) Schematic representation of site-specific conjugation to the C-terminal cys-tag of cys-diabody and cys-minibody antibody fragments, respectively. (B) Reduction and conjugation of Alexa Fluor 488 Maleimide (using the example of the cys-diabody) results in monomeric fragments migrating under non-reducing conditions in SDS-PAGE shown as Coomassie stain (left panel) and fluorescence (right panel). (C) Size exclusion chromatography analysis comparing unconjugated (black) and mal-DFo conjugated (grey) antibody fragments (using Superdex 75 column for cys-diabodies and Superdex 200 column for cys-minibodies. Figure S3. Obinutuzumab (GA101)-based antibody fragments retain type II binding characteristics. Figure S4. Immunoreactive fractions of radiolabeled antibody fragments were determined by cell binding studies using CD20 positive Ramos cells and CD20 negative Bc-1 cells. Shown is one representative plot for 124I-GAcDb. Immunoreactive fractions for obinutuzumab (GA1010)-based fragments ranged from 65-85 %. Figure S5 89Zr-GAcMb immunoPET imaging of huCD20TM. Figure S6 Immunohistochemical staining of human CD20 expression in murine 38C13 B-cell lymphoma allografts.
Supplemental Figure 3 from Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Authors: Infante Jeffrey R. , Hollebecque Antoine , Postel-Vinay Sophie , Bauer Todd M. , Blackwood Elizabeth M. , Evangelista Marie , Mahrus Sami , Peale Franklin V. , Lu Xuyang , Sahasranaman Srikumar , Zhu Rui , Chen Yuan , Ding Xiao , Murray Elaine R. , Schutzman Jennifer L. , Lauchle Jennifer O. , Soria Jean-Charles , LoRusso Patricia M.
Published: April 2023

Supplemental Figure 3. Clinical trial tumor immunohistochemistry. Representative images from tumor biopsies were analyzed for pCDK1/2 and Ki-67expression. Representative images from a patient with NSCLC and unknown p53 mutation status were obtained 24 hours after administration of GDC-0425 alone (A, B), 48 hours after gemcitabine alone (C, D) and at a time point that was both 24 hours after GDC-0425 and 48 hours after gemcitabine (E, F). Quantitation of percent tumor cell Ki-67 positivity varied minimally between biopsies (G); pCDK1/2 increased from baseline after gemcitabine treatment, whereas the combination of GDC-0425 given 24 hours after gemcitabine suppressed the increase in pCDK1/2. Scale bar=40 Âµm.
Supplementary Figure Legends from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Authors: Pikman Yana , Alexe Gabriela , Roti Giovanni , Conway Amy Saur , Furman Andrew , Lee Emily S. , Place Andrew E. , Kim Sunkyu , Saran Chitra , Modiste Rebecca , Weinstock David M. , Harris Marian , Kung Andrew L. , Silverman Lewis B. , Stegmaier Kimberly
Published: April 2023

Figure legends for the supplementary figures
Supplemetary Figure S4 from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis
Authors: Fornari Francesca , Pollutri Daniela , Patrizi Clarissa , La Bella Tiziana , Marinelli Sara , Casadei Gardini Andrea , Marisi Giorgia , Baron Toaldo Marco , Baglioni Michele , Salvatore Veronica , Callegari Elisa , Baldassarre Maurizio , Galassi Marzia , Giovannini Catia , Cescon Matteo , Ravaioli Matteo , Negrini Massimo , Bolondi Luigi , Gramantieri Laura
Published: April 2023

Figure S4. (A, E) Box plot graphs of serum AFP in HCC patients with high and low miR-221 or caspase-3 expression levels. High and low miR-221 or caspase-3 expression was identified on the basis of the median value.
Supplementary Tables and Figure Legends from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis
Authors: Fornari Francesca , Pollutri Daniela , Patrizi Clarissa , La Bella Tiziana , Marinelli Sara , Casadei Gardini Andrea , Marisi Giorgia , Baron Toaldo Marco , Baglioni Michele , Salvatore Veronica , Callegari Elisa , Baldassarre Maurizio , Galassi Marzia , Giovannini Catia , Cescon Matteo , Ravaioli Matteo , Negrini Massimo , Bolondi Luigi , Gramantieri Laura
Published: April 2023

Supplementary Table S1. Characteristics of surgical HCC patients analysed in this study. Supplementary Table S2. Patients assessed for circulating miR-221. Supplementary Table S3. Primer sequences and PCR conditions for the cloning experiment. Supplementary Table S4. Primer sequences and PCR conditions. Supplementary Table S5. Antibodies used in Western blot analysis.
Supplementary Figure 1 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Authors: Pikman Yana , Alexe Gabriela , Roti Giovanni , Conway Amy Saur , Furman Andrew , Lee Emily S. , Place Andrew E. , Kim Sunkyu , Saran Chitra , Modiste Rebecca , Weinstock David M. , Harris Marian , Kung Andrew L. , Silverman Lewis B. , Stegmaier Kimberly
Published: April 2023

LEE011 is antagonistic with methotrexate, mercaptopurine, and L-asparaginase, and synergistic with doxorubicin using Excess over Bliss analysis.
Supplementary Tables and Figures from Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?
Authors: Goldstein Jennifer B. , Wu William , Borras Ester , Masand Gita , Cuddy Amanda , Mork Maureen E. , Bannon Sarah A. , Lynch Patrick M. , Rodriguez-Bigas Miguel , Taggart Melissa W. , Wu Ji , Scheet Paul , Kopetz Scott , You Y. Nancy , Vilar Eduardo
Published: April 2023

Supplementary Table 1. Patient Demographic Characteristics. *2 patients with metachronous tumors, 1 poor and 1 moderate; **One patient with both pre- and posttreatment IHC and MSI testing. Supplementary Table 2. Tumor characteristics and results of the IHC and MSI analysis of those cases exhibiting loss of MSH6 after neoadjuvant treatment. Abbreviations: yp, pathologic stage after neoadjuvant treatment; NT, not tested; pre-tx, pre-treatment; post-tx, post-treatment; MSS, microsatellite stable; MSI-L, microsatellite low. Supplementary Table 3. MSI and IHC Analysis of in vivo pre- and post-treatment data. Abbreviations: yp, pathologic stage after neoadjuvant treatment; pre-tx, pre-treatment; post-tx, post-treatment; MSS, microsatellite stable; MSI-L, microsatellite low. Supplementary Table 4. PDX Patient Demographic Characteristics (n = 5) Supplementary Figure 1. Confirmation of MLH1 loss in the cell line HCT116 was performed via Sanger sequencing (A) and Western Blot (B) Supplementary Figure 2. In vitro treatment method. MMR deficient (HCT116) and proficient (HCT116+Ch3) isogenic cell lines were exposed to treatment every 48 hours for 3 cycles. On Day 1, 500,000 cells/10 mm plate were seeded and allowed to grow exponentially for 24-48 hours. Cells were then treated with radiation or drug. After 48hrs, the cells were allowed to grow in drug-free medium until confluency. Cells were split and allowed to grow again in drug-free medium for 48 hours before being treated with the next round of treatment. This process was repeated for 3 cycles. After 48 hours of the 3rd treatment, the slides were fixed with 4% paraformaldehyde.
Supplementary Figure S1 from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis
Authors: Fornari Francesca , Pollutri Daniela , Patrizi Clarissa , La Bella Tiziana , Marinelli Sara , Casadei Gardini Andrea , Marisi Giorgia , Baron Toaldo Marco , Baglioni Michele , Salvatore Veronica , Callegari Elisa , Baldassarre Maurizio , Galassi Marzia , Giovannini Catia , Cescon Matteo , Ravaioli Matteo , Negrini Massimo , Bolondi Luigi , Gramantieri Laura
Published: April 2023

Figure S1. Schematic flow chart of HCC patients.
Supplementary Tables from Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth
Authors: Li Ming , Radvanyi Laszlo , Yin Bingnan , Rycaj Kiera , Li Jia , Chivukula Raghavender , Lin Kevin , Lu Yue , Shen JianJun , Chang David Z. , Li Donghui , Johanning Gary L. , Wang-Johanning Feng
Published: April 2023

Supplementary Table 1-4
Supplementary Figures from Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth
Authors: Li Ming , Radvanyi Laszlo , Yin Bingnan , Rycaj Kiera , Li Jia , Chivukula Raghavender , Lin Kevin , Lu Yue , Shen JianJun , Chang David Z. , Li Donghui , Johanning Gary L. , Wang-Johanning Feng
Published: April 2023

sFig. 1 to 6
Supplementary File 3 from Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens
Authors: Andersen Courtney L. , Sikora Matthew J. , Boisen Michelle M. , Ma Tianzhou , Christie Alec , Tseng George , Park Yongseok , Luthra Soumya , Chandran Uma , Haluska Paul , Mantia-Smaldone Gina M. , Odunsi Kunle , McLean Karen , Lee Adrian V. , Elishaev Esther , Edwards Robert P. , Oesterreich Steffi
Published: April 2023

Supplementary File 3 contains the available pre- and post-treatment CA-125 data for our patient cohort.
Supplementary File 2 from Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens
Authors: Andersen Courtney L. , Sikora Matthew J. , Boisen Michelle M. , Ma Tianzhou , Christie Alec , Tseng George , Park Yongseok , Luthra Soumya , Chandran Uma , Haluska Paul , Mantia-Smaldone Gina M. , Odunsi Kunle , McLean Karen , Lee Adrian V. , Elishaev Esther , Edwards Robert P. , Oesterreich Steffi
Published: April 2023

Supplementary File 2 contains the ordered gene lists for the heat maps in Figure 1.
Figures S1 and S2 from MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer
Authors: Gunda Venugopal , Souchek Joshua , Abrego Jaime , Shukla Surendra K. , Goode Gennifer D. , Vernucci Enza , Dasgupta Aneesha , Chaika Nina V. , King Ryan J. , Li Sicong , Wang Shuo , Yu Fang , Bessho Tadayoshi , Lin Chi , Singh Pankaj K.
Published: April 2023

Figure S1. BrPA inhibits MUC1-mediated nucleotide metabolism. Figure S2. Immunohistochemical staining for MUC1 in tumor sections.
Supplementary Figures from Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens
Authors: Andersen Courtney L. , Sikora Matthew J. , Boisen Michelle M. , Ma Tianzhou , Christie Alec , Tseng George , Park Yongseok , Luthra Soumya , Chandran Uma , Haluska Paul , Mantia-Smaldone Gina M. , Odunsi Kunle , McLean Karen , Lee Adrian V. , Elishaev Esther , Edwards Robert P. , Oesterreich Steffi
Published: April 2023

This document contains the supplementary figures for the manuscript.
supplemental legend from Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
Authors: Lawson Keith A. , Mostafa Ahmed A. , Shi Zhong Qiao , Spurrell Jason , Chen Wenqian , Kawakami Jun , Gratton Kathy , Thakur Satbir , Morris Donald G.
Published: April 2023

supplemental legend
Supplementary Materials from Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer
Authors: Xie Yang , Lu Wei , Wang Shidan , Tang Ximing , Tang Hao , Zhou Yunyun , Moran Cesar , Behrens Carmen , Roth Jack A. , Zhou Qinghua , Johnson David H. , Swisher Stephen G. , Heymach John V. , Papadimitrakopoulou Vassiliki A. , Xiao Guanghua , Minna John D. , Wistuba Ignacio I.
Published: April 2023

Supplementary Table S1. Summary of Tables and Figures. Supplementary Table S2. Propensity score-matched coefficients for each variable using logistic regression. Supplementary Table S3. Propensity score matching results. In Supplementary Table 4. The numbers of patients with and without ACT by stage after propensity score matching in ADC and SCC patient groups. Supplementary Table S5. The dynamic range and correlation between expression levels measured in 30 pairs of FFPE and frozen samples of each gene measured by the nCounter gene expression assay. Supplementary Table S6. Multivariate analysis for validating the prognostic performance of the 12-gene signature measured from FFPE samples after adjusting for other patient characteristics in the 147 stage I ADC patients without ACT. Supplementary Figure S1. Determining the cutoff value of pre-defined risk scores for predicted high-risk and low-risk groups using the assay development cohort. Supplementary Figure S2. (C) Time-dependent ROC curves in (A) ADC patients and (B) stage I ADC patients. Supplementary Figure S3. The ROC curve for the predictive analysis.
Supplemental Figure 3 from Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
Authors: Lawson Keith A. , Mostafa Ahmed A. , Shi Zhong Qiao , Spurrell Jason , Chen Wenqian , Kawakami Jun , Gratton Kathy , Thakur Satbir , Morris Donald G.
Published: April 2023

Mouse body weights during treatment.
Supplemental Materials from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Ramalingam Suresh S. , Blais Normand , Mazieres Julien , Reck Martin , Jones C. Michael , Juhasz Erzsebet , Urban Laszlo , Orlov Sergey , Barlesi Fabrice , Kio Ebenezer , Keiholz Ulrich , Qin Qin , Qian Jiang , Nickner Caroline , Dziubinski Juliann , Xiong Hao , Ansell Peter , McKee Mark , Giranda Vincent , Gorbunova Vera
Published: April 2023

Supplemental Table 1. Demographics and baseline characteristics by histology: squamous cell Supplemental Table 2. Demographics and baseline characteristics by histology: non-squamous cell Supplemental Table 3. Mean {plus minus} SD pharmacokinetic parameters of veliparib on cycle 1 day 3 Supplemental Table 4. Mean {plus minus} SD (median) plasma concentrations of paclitaxel and carboplatin at 5 min before ending paclitaxel and carboplatin infusions, respectively Supplemental Figure 1: Progression-free survival (A) and overall survival (B) in responders and non-responders
Supplemental Figure 2 from Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
Authors: Lawson Keith A. , Mostafa Ahmed A. , Shi Zhong Qiao , Spurrell Jason , Chen Wenqian , Kawakami Jun , Gratton Kathy , Thakur Satbir , Morris Donald G.
Published: April 2023

In vitro and in vivo sunitinib dose response.
Supplemental Figure 1 from Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
Authors: Lawson Keith A. , Mostafa Ahmed A. , Shi Zhong Qiao , Spurrell Jason , Chen Wenqian , Kawakami Jun , Gratton Kathy , Thakur Satbir , Morris Donald G.
Published: April 2023

Chemokine expression in reovirus infected RENCA cells at 12 hours.
Suppl Table S3 from Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
Authors: Kelly Kevin , Mejia Alex , Suhasini Avvaru N. , Lin An-Ping , Kuhn John , Karnad Anand B. , Weitman Steven , Aguiar Ricardo C.T.
Published: April 2023

ADME Screening Panel (69 genes - 543 SNPs).
Supplemental Table 2 from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Raje Noopur S. , Faber Edward A. , Richardson Paul G. , Schiller Gary , Hohl Raymond J. , Cohen Adam D. , Forero Andres , Carpenter Susan , Nguyen Tuan S. , Conti Ilaria , Kaiser Christopher J. , Cronier Damien M. , Wooldridge James E. , Anderson Kenneth C.
Published: April 2023

Bortezomib pharmacokinetic parameters following a single intravenous 1.3 mg/m2 bolus dose and varying single intravenous doses of tabalumab
Suppl Fig 1 from Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
Authors: Kelly Kevin , Mejia Alex , Suhasini Avvaru N. , Lin An-Ping , Kuhn John , Karnad Anand B. , Weitman Steven , Aguiar Ricardo C.T.
Published: April 2023

PDE4B and PDE4D expression.
Supplemental Figure Legend from Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Raje Noopur S. , Faber Edward A. , Richardson Paul G. , Schiller Gary , Hohl Raymond J. , Cohen Adam D. , Forero Andres , Carpenter Susan , Nguyen Tuan S. , Conti Ilaria , Kaiser Christopher J. , Cronier Damien M. , Wooldridge James E. , Anderson Kenneth C.
Published: April 2023

Percentage Change from Baseline (PCB) for B-cells (CD19+) and Immunoglobulins (Ig)at 20-day time intervals post-baseline.
supplemental figure from Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer
Authors: Toffoli Giuseppe , Sharma Manish R. , Marangon Elena , Posocco Bianca , Gray Elizabeth , Mai Quan , Buonadonna Angela , Polite Blase N. , Miolo Gianmaria , Tabaro Gianna , Innocenti Federico
Published: April 2023

Supplementary Figure 1. Progression-free survival (PFS) overall (A), by UGT1A1 genotype (B), and by irinotecan dose (C).
Supplemental Table from Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer
Authors: Toffoli Giuseppe , Sharma Manish R. , Marangon Elena , Posocco Bianca , Gray Elizabeth , Mai Quan , Buonadonna Angela , Polite Blase N. , Miolo Gianmaria , Tabaro Gianna , Innocenti Federico
Published: April 2023

Supplementary Table 1. Toxicities during the first cycle of FOLFIRI plus bevacizumab. Number of patients (%) is indicated. Toxicities were included if they occurred in at least 10% of patients or if they were grade 3 or greater, and if they were at least possibly related to treatment.
Supplemental legend from RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer
Authors: Wang Yifan , Gudikote Jayanthi , Giri Uma , Yan Jun , Deng Weiye , Ye Rui , Jiang Wen , Li Nan , Hobbs Brian P. , Wang Jing , Swisher Stephen G. , Fujimoto Junya , Wistuba Ignacio I. , Komaki Ritsuko , Heymach John V. , Lin Steven H.
Published: April 2023

Supplemental legend
Supplementary Table 3 from High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype
Authors: Dennison Jennifer B. , Shahmoradgoli Maria , Liu Wenbin , Ju Zhenlin , Meric-Bernstam Funda , Perou Charles M. , Sahin Aysegul A. , Welm Alana , Oesterreich Steffi , Sikora Matthew J. , Brown Robert E. , Mills Gordon B.
Published: April 2023

Proteins differentially expressed in Reactive subtype (Excel sheet).
Suppl. Tables S1-S5 from RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer
Authors: Wang Yifan , Gudikote Jayanthi , Giri Uma , Yan Jun , Deng Weiye , Ye Rui , Jiang Wen , Li Nan , Hobbs Brian P. , Wang Jing , Swisher Stephen G. , Fujimoto Junya , Wistuba Ignacio I. , Komaki Ritsuko , Heymach John V. , Lin Steven H.
Published: April 2023

Supplementary Table S1. List of all primers and oligos used in this study. Supplementary Table S2. Subcellular staining locations of 12 candidate marker proteins in tumor microarray. Supplementary Table S3. Staining results for 17 candidate marker protein variables in the tumor microarray. Supplementary Table S4. Univariate and multivariate analyses of associations between clinical variables and RAD50 expression for OS, LRRFS, DMFS and DFS among 127 NSCLC patients. Supplementary Table S5. Univariate and multivariate analyses of associations between all the 17 markers and OS, LRRFS, DMFS and DFS among 127 NSCLC patients.
Suppl. Methods from RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer
Authors: Wang Yifan , Gudikote Jayanthi , Giri Uma , Yan Jun , Deng Weiye , Ye Rui , Jiang Wen , Li Nan , Hobbs Brian P. , Wang Jing , Swisher Stephen G. , Fujimoto Junya , Wistuba Ignacio I. , Komaki Ritsuko , Heymach John V. , Lin Steven H.
Published: April 2023

Supplementary Methods
Figure S3 from In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development
Authors: Jaworski Felipe M. , Gentilini Lucas D. , Gueron Geraldine , Meiss Roberto P. , Ortiz Emiliano G. , Berguer Paula M. , Ahmed Asif , Navone Nora , Rabinovich Gabriel A. , Compagno Daniel , Laderach Diego J. , Vazquez Elba S.
Published: April 2023

Bioinformatic analysis of human prostate adenocarcinoma microarray datasets. Oncomine was used to browse gene expression microarrays data. Box plots depict prostate statistics derived from Grasso et al. LGALS1, CD34, FLT1, FLT4, VEGFA, VEGFC, VCAM1, CD28, CD80 and CD86 were assessed. Each box plot shows the expression levels for each gene in 1) normal prostate gland and 2) prostate adenocarcinoma. * indicates P<0.05
Supplementary Table 2 from The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer
Authors: Governa Valeria , Trella Emanuele , Mele Valentina , Tornillo Luigi , Amicarella Francesca , Cremonesi Eleonora , Muraro Manuele Giuseppe , Xu Hui , Droeser Raoul , Däster Silvio R. , Bolli Martin , Rosso Raffaele , Oertli Daniel , Eppenberger-Castori Serenella , Terracciano Luigi M. , Iezzi Giandomenica , Spagnoli Giulio C.
Published: April 2023

Clinical-phatological characteristics of the CRC patient cohort and their association with levels of CD8+ and CD66b+ cell infiltrate.
Supplementary Table 1 from The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer
Authors: Governa Valeria , Trella Emanuele , Mele Valentina , Tornillo Luigi , Amicarella Francesca , Cremonesi Eleonora , Muraro Manuele Giuseppe , Xu Hui , Droeser Raoul , Däster Silvio R. , Bolli Martin , Rosso Raffaele , Oertli Daniel , Eppenberger-Castori Serenella , Terracciano Luigi M. , Iezzi Giandomenica , Spagnoli Giulio C.
Published: April 2023

Clinical-phatological characteristics of the CRC patient cohort and their association with levels of CD66b+ cell infiltrate.
Supplementary Figure 3 from The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer
Authors: Governa Valeria , Trella Emanuele , Mele Valentina , Tornillo Luigi , Amicarella Francesca , Cremonesi Eleonora , Muraro Manuele Giuseppe , Xu Hui , Droeser Raoul , Däster Silvio R. , Bolli Martin , Rosso Raffaele , Oertli Daniel , Eppenberger-Castori Serenella , Terracciano Luigi M. , Iezzi Giandomenica , Spagnoli Giulio C.
Published: April 2023

CD8+/PBN cross-talk is contact dependent. (A) Cumulative flow-cytometry histograms documenting CD69 expression in CD8+ T cells activated by using different concentrations of surface bound anti-CD3 (TR66, 0.5 and 2Î¼g/ml) and soluble anti CD28 (1Î¼g/ml) upon overnight co-culture in the presence or absence of neutrophils. (B) Representative dot plots showing CD69 expression in peripheral blood CD8+ cells stimulated by suboptimal concentrations of anti-CD3/ anti-CD28 in presence or absence of autologous PBN and in control and transwell conditions, preventing cell-cell contact. (C) Representative plots documenting the effects of anti CD11a mAb on CD69 expression in CD8+ T cells activated by a suboptimal concentration of anti-CD3/anti-CD28 in the presence of autologous PBNs. (D) CFSE dilution was used to assess CD8+ T cell proliferation in cultured stimulated with suboptimal concentrations of anti CD3 mAbs and anti CD28 in the presence or absence of PBN.
Supplementary Figure S3 from A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients
Authors: van Vlodrop Iris J.H. , Joosten Sophie C. , De Meyer Tim , Smits Kim M. , Van Neste Leander , Melotte Veerle , Baldewijns Marcella M.L.L. , Schouten Leo J. , van den Brandt Piet A. , Jeschke Jana , Yi Joo Mi , Schuebel Kornel E. , Ahuja Nita , Herman James G. , Aarts Maureen J. , Bosman Fred T. , Van Criekinge Wim , van Engeland Manon
Published: April 2023

Supplementary Figure S3. Cause-specific overall survival curves for candidate genes in hospital-based ccRCC series (related to Supplementary Table S5). Kaplan-Meier curves of CSPG4 (A), KRT7 (B), QPCT (C), RGMA (D), and SORL1 (E) analyzed for overall survival in hospital-based series. Number at risk: number of patients surviving at each time point. U: unmethylated; M: methylated.
Legend from The Interplay Between Neutrophils and CD8+ T Cells Improves Survival in Human Colorectal Cancer
Authors: Governa Valeria , Trella Emanuele , Mele Valentina , Tornillo Luigi , Amicarella Francesca , Cremonesi Eleonora , Muraro Manuele Giuseppe , Xu Hui , Droeser Raoul , Däster Silvio R. , Bolli Martin , Rosso Raffaele , Oertli Daniel , Eppenberger-Castori Serenella , Terracciano Luigi M. , Iezzi Giandomenica , Spagnoli Giulio C.
Published: April 2023

Supplementary legend figures
Supplementary Figure Legends and Supplementary Tables from A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients
Authors: van Vlodrop Iris J.H. , Joosten Sophie C. , De Meyer Tim , Smits Kim M. , Van Neste Leander , Melotte Veerle , Baldewijns Marcella M.L.L. , Schouten Leo J. , van den Brandt Piet A. , Jeschke Jana , Yi Joo Mi , Schuebel Kornel E. , Ahuja Nita , Herman James G. , Aarts Maureen J. , Bosman Fred T. , Van Criekinge Wim , van Engeland Manon
Published: April 2023

File containing Supplementary Tables S1-S7 and Legends to Supplementary Figures S1-S4. Supplementary Table S1. Primers for promoter methylation analysis by MSP of the 43 candidate genes. Supplementary Table S2. Primers for mRNA expression analysis by qRT-PCR for 22 genes. Supplementary Table S3. Candidate gene selection. Supplementary Table S4. Validation of expression microarrays and MBD-NGS by MSP. Supplementary Table S5. Candidate gene promoter methylation associated with patient and tumor characteristics - hospital-based series. Supplementary Table S6. Hazard ratio's with 95% confidence intervals and p-values, including model fit according to Harrell's C and AIC, for the single markers, all possible two- and three-marker panels, and the four-marker panel for both the age- and sex-adjusted models and the multivariable models in the hospital-based series. Supplementary Table S7. Hazard ratio's with 95% confidence intervals and p-values, including model fit according to Harrell's C and AIC, for the single markers, all possible two- and three-marker panels, and the four-marker panel for both the age- and sex-adjusted models and the multivariable models in the population-based series. Supplementary Figure S1. Methylation analysis of GREM1, LAD1, NEFH and NEURL by methylation-specific PCR (MSP) in the hospital- and population-based series and in the TCGA series. Supplementary Figure S2. Validation of up-regulation of gene expression after demethylation with DAC by qRT-PCR for 22 genes. Supplementary Figure S3. Cause-specific overall survival curves for candidate genes in hospital-based ccRCC series (related to Supplementary Table S5). Supplementary Figure S4. Cause-specific overall survival curves for GREM1, LAD1, NEFH, and NEURL in hospital- and population-based ccRCC series (related to Table 1 and Table 2).
Supplementary Tables 1-8, Supplementary Figure 1 from Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis
Authors: Wynants Laure , Timmerman Dirk , Verbakel Jan Y. , Testa Antonia , Savelli Luca , Fischerova Daniela , Franchi Dorella , Van Holsbeke Caroline , Epstein Elisabeth , Froyman Wouter , Guerriero Stefano , Rossi Alberto , Fruscio Robert , Leone Francesco PG , Bourne Tom , Valentin Lil , Van Calster Ben
Published: April 2023

Supplementary Table 1. Validated prediction models; Supplementary Table 2. Data contributed to dataset 1 per center; Supplementary Table 3. Net Benefit of the LR2 model by IOTA (LR2), the Risk of Malignancy Index (RMI at cut-off 200), the IOTA Simple Rules Risk scoring system (SRRisks), and the IOTA ADNEX model in all patients; Supplementary Table 4. Difference between the Net Benefit (NB) of a model and that of the best default strategy; Supplementary Table 5. Difference between the Net Benefit of a model and that of the best default strategy; Supplementary Table 6. Difference between the Net Benefit of each model and the Net Benefit of the best model (NB best model - NB model) in premenopausal patients; Supplementary Table 7. Net Benefit of the International Ovarian Tumor Analysis (IOTA) logistic regression model 2 (LR2), the Risk of Malignancy Index (RMI, cut-off 200), and the Risk of Ovarian Malignancy Algorithm (ROMA) (n=360, 40% malignant tumors); Supplementary Table 8. Difference between the Net Benefit (NB) of a model and that of the best default strategy (NB model - NB best default) and between the NB of the best model and that of each of the other models; Supplementary Figure 1. Decision curves representing the Net Benefit of the Risk of Malignancy Index (RMI) with cut-offs 25, 100, 200, 250 and 450, the International Ovarian Tumor Analysis (IOTA) logistic regression model 2 (LR2), and the IOTA ADNEX model (ADNEX) and the ADNEX model without CA125 measurements.
Table S2 from Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant
Authors: Hsu Pei-Yin , Wu Victoria Shang , Kanaya Noriko , Petrossian Karineh , Hsu Hang-Kai , Nguyen Duc , Schmolze Daniel , Kai Masaya , Liu Chun-Yu , Lu Hannah , Chu Peiguo , Vito Courtney A. , Kruper Laura , Mortimer Joanne , Chen Shiuan
Published: April 2023

Table S2. Highly expressed loci in COH-SC31 in relation to COH-SC1
NACT Supplementary Methods - revised from Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Authors: Lo Charlotte S. , Sanii Sanaz , Kroeger David R. , Milne Katy , Talhouk Aline , Chiu Derek S. , Rahimi Kurosh , Shaw Patricia A. , Clarke Blaise A. , Nelson Brad H.
Published: April 2023

This file contains revised supplementary methods for the revised manuscript.
NACT Supplementary Figures - revised from Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Authors: Lo Charlotte S. , Sanii Sanaz , Kroeger David R. , Milne Katy , Talhouk Aline , Chiu Derek S. , Rahimi Kurosh , Shaw Patricia A. , Clarke Blaise A. , Nelson Brad H.
Published: April 2023

Supplementary Fig. S1. CONSORT diagram of patient selection and cohort construction. Supplementary Fig. S2. Plasma cell infiltrates before and after NACT. The data was generated and analyzed as in Figure 1. Supplementary Fig. S3. Example of intraepithelial PD-1+ FoxP3+ TIL in a quadruple-color IHC of PD-L1 CD8 PD-1 FoxP3. Supplementary Fig. S4. Unsupervised clustering of TIL based on post-NACT data.
Figure S1-6 from Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant
Authors: Hsu Pei-Yin , Wu Victoria Shang , Kanaya Noriko , Petrossian Karineh , Hsu Hang-Kai , Nguyen Duc , Schmolze Daniel , Kai Masaya , Liu Chun-Yu , Lu Hannah , Chu Peiguo , Vito Courtney A. , Kruper Laura , Mortimer Joanne , Chen Shiuan
Published: April 2023

Figure S1. Characterization of two HR+/HER2+ breast patient-derived xenografts (PDXs), COH-SC1 and COH-SC31. Figure S2. Uterus and tumor weight of mice bearing COH-SC1 and COH-SC31 tumors in respond to estrogen treatment. Figure S3. Observations of body weight in response to drug treatment in vivo. Figure S4: Pathway analysis of up-regulated loci in COH-SC1 and COH-SC31 transcriptomes. Figure S5: Expression patterns of up-regulated proteins in COH-SC1 and COH-SC31 PDXs assayed by RPPA. Figure S6 In vivo efficacy examination of trastuzumab and/or MLN0128 on COH-SC1 PDX.
Supplementary Table ST2 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Salvucci Manuela , Würstle Maximilian L. , Morgan Clare , Curry Sarah , Cremona Mattia , Lindner Andreas U. , Bacon Orna , Resler Alexa J. , Murphy Áine C. , O'Byrne Robert , Flanagan Lorna , Dasgupta Sonali , Rice Nadege , Pilati Camilla , Zink Elisabeth , Schöller Lisa M. , Toomey Sinead , Lawler Mark , Johnston Patrick G. , Wilson Richard , Camilleri-Broët Sophie , Salto-Tellez Manuel , McNamara Deborah A. , Kay Elaine W. , Laurent-Puig Pierre , Van Schaeybroeck Sandra , Hennessy Bryan T. , Longley Daniel B. , Rehm Markus , Prehn Jochen H.M.
Published: April 2023

Unadjusted and multivariate Cox proportional hazards analyses to examine the association of APOPTO-CELL and APOPTO-CELL-PC3 signatures with DFS in n=157 stage III patients of the expansion cohort.
Supplemental Table 1 from CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas
Authors: Venkataramani Vivek , Küffer Stefan , Cheung Kenneth C.P. , Jiang Xuejun , Trümper Lorenz , Wulf Gerald G. , Ströbel Philipp
Published: April 2023

Supplementary Table 1: list of identified YAP/TAZ direct target genes.
Supplementary Table ST1 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Salvucci Manuela , Würstle Maximilian L. , Morgan Clare , Curry Sarah , Cremona Mattia , Lindner Andreas U. , Bacon Orna , Resler Alexa J. , Murphy Áine C. , O'Byrne Robert , Flanagan Lorna , Dasgupta Sonali , Rice Nadege , Pilati Camilla , Zink Elisabeth , Schöller Lisa M. , Toomey Sinead , Lawler Mark , Johnston Patrick G. , Wilson Richard , Camilleri-Broët Sophie , Salto-Tellez Manuel , McNamara Deborah A. , Kay Elaine W. , Laurent-Puig Pierre , Van Schaeybroeck Sandra , Hennessy Bryan T. , Longley Daniel B. , Rehm Markus , Prehn Jochen H.M.
Published: April 2023

Patient clinicopathological and demographic characteristics in the patients of the discovery, expansion and validation cohorts.
Supplemental Figures 1-5 from CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas
Authors: Venkataramani Vivek , Küffer Stefan , Cheung Kenneth C.P. , Jiang Xuejun , Trümper Lorenz , Wulf Gerald G. , Ströbel Philipp
Published: April 2023

Supplementary Figure 1. CD31low cells in human angiosarcomas and in angiosarcoma-derived cell lines; Supplementary Figure 2. CD31low angiosarcoma cells are more resistant against doxorubicin-induced cell death; Supplementary Figure 3. Pharmacological screen in CD31high angiosarcoma cells identified ROS scavengers retrieving colony formation capacity; Supplementary Figure 4. Validation of the CD31-YAP-redox-axis in normal and malignant endothelial cells; Supplementary Figure 5. EndoMT transcription factor Slug is enriched in CD31low cells.
Supplementary Methods SM3 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Salvucci Manuela , Würstle Maximilian L. , Morgan Clare , Curry Sarah , Cremona Mattia , Lindner Andreas U. , Bacon Orna , Resler Alexa J. , Murphy Áine C. , O'Byrne Robert , Flanagan Lorna , Dasgupta Sonali , Rice Nadege , Pilati Camilla , Zink Elisabeth , Schöller Lisa M. , Toomey Sinead , Lawler Mark , Johnston Patrick G. , Wilson Richard , Camilleri-Broët Sophie , Salto-Tellez Manuel , McNamara Deborah A. , Kay Elaine W. , Laurent-Puig Pierre , Van Schaeybroeck Sandra , Hennessy Bryan T. , Longley Daniel B. , Rehm Markus , Prehn Jochen H.M.
Published: April 2023

Detailed description of the survival analyses performed in both primary and exploratory studies.
Supplementary Data from Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer
Authors: Wang Erjian , Nickens Dana J. , Bello Akintunde , Khosravan Reza , Amantea Michael , Wilner Keith D. , Parivar Kourosh , Tan Weiwei
Published: April 2023

Supplementary Table and Development of the population PK model
Supplementary Methods SM2 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Salvucci Manuela , Würstle Maximilian L. , Morgan Clare , Curry Sarah , Cremona Mattia , Lindner Andreas U. , Bacon Orna , Resler Alexa J. , Murphy Áine C. , O'Byrne Robert , Flanagan Lorna , Dasgupta Sonali , Rice Nadege , Pilati Camilla , Zink Elisabeth , Schöller Lisa M. , Toomey Sinead , Lawler Mark , Johnston Patrick G. , Wilson Richard , Camilleri-Broët Sophie , Salto-Tellez Manuel , McNamara Deborah A. , Kay Elaine W. , Laurent-Puig Pierre , Van Schaeybroeck Sandra , Hennessy Bryan T. , Longley Daniel B. , Rehm Markus , Prehn Jochen H.M.
Published: April 2023

Detailed description of the measurements used as inputs for the apoptosis-based signatures in the discovery, expansion and validation cohorts.
Supplementary Methods SM1 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Salvucci Manuela , Würstle Maximilian L. , Morgan Clare , Curry Sarah , Cremona Mattia , Lindner Andreas U. , Bacon Orna , Resler Alexa J. , Murphy Áine C. , O'Byrne Robert , Flanagan Lorna , Dasgupta Sonali , Rice Nadege , Pilati Camilla , Zink Elisabeth , Schöller Lisa M. , Toomey Sinead , Lawler Mark , Johnston Patrick G. , Wilson Richard , Camilleri-Broët Sophie , Salto-Tellez Manuel , McNamara Deborah A. , Kay Elaine W. , Laurent-Puig Pierre , Van Schaeybroeck Sandra , Hennessy Bryan T. , Longley Daniel B. , Rehm Markus , Prehn Jochen H.M.
Published: April 2023

Detailed description of the patients data handling and inclusion criteria for downstream analyses of the discovery, expansion and validation cohorts.
Supplementary Figures 1-3 from Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer
Authors: Liang Qiaoyi , Chiu Jonathan , Chen Yingxuan , Huang Yanqin , Higashimori Akira , Fang Jingyuan , Brim Hassan , Ashktorab Hassan , Ng Siew Chien , Ng Simon Siu Man , Zheng Shu , Chan Francis Ka Leung , Sung Joseph Jao Yiu , Yu Jun
Published: April 2023

Supplementary Figure S1. Good consistency in quantification of nusG/F. nucleatum (Fn) was achieved by two experimenters using our convenient platform. Two samples with outlier highlevels of Fn were further excluded so as to show more clearly the good consistency even in samples with relatively low levels of Fn. Abundances of Fn were shown in arbitrary unit; Supplementary Figure S2. Contaminant human DNA had little effect on the new qPCR platform. (A) A representative example of qPCR evaluation of the internal control on a mixture of 10 randomly selected fecal samples added with different concentrations of human DNA. (B) A representative example of duplex qPCR evaluation of the internal control and F. nucleatum on a randomly selected fecal sample added with different concentrations of human DNA; Supplementary Figure S3. Metagenome sequencing data showed that combination with other markers improved the diagnostic ability of Fusobacterium nucleatum (Fn) for colorectal cancer. ROC curves for Fn alone and simple linear combination of all the five selected bacterial marker candidates including Fn, Bacteroides clarus (Bc), Clostridium hathewayi (Ch), one undefined species (labeled as m7), and Roseburia intestinalis (Ri). The best cutoff values that maximize sensitivity and specificity were determined for Fn and 5-markers individually in the metagenome sequencing cohort with 74 CRC patients and 54 controls. AUROC, area under the receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value.
Supplementary Figure S2 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Salvucci Manuela , Würstle Maximilian L. , Morgan Clare , Curry Sarah , Cremona Mattia , Lindner Andreas U. , Bacon Orna , Resler Alexa J. , Murphy Áine C. , O'Byrne Robert , Flanagan Lorna , Dasgupta Sonali , Rice Nadege , Pilati Camilla , Zink Elisabeth , Schöller Lisa M. , Toomey Sinead , Lawler Mark , Johnston Patrick G. , Wilson Richard , Camilleri-Broët Sophie , Salto-Tellez Manuel , McNamara Deborah A. , Kay Elaine W. , Laurent-Puig Pierre , Van Schaeybroeck Sandra , Hennessy Bryan T. , Longley Daniel B. , Rehm Markus , Prehn Jochen H.M.
Published: April 2023

Kaplan-Meier estimates for disease-free and overall survival for n=120 stage III patients of the discovery cohort categorized based on TN staging, tumor location and lymphovascular invasion. Additional exploratory analyses investigated the prognostic value of the APOPTO-CELL-PC3 signature within each sub-group identified by the clinical features.
Supplementary Figure legends from Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models
Authors: Cook Sangar Michelle L. , Genovesi Laura A. , Nakamoto Madison W. , Davis Melissa J. , Knobluagh Sue E. , Ji Pengxiang , Millar Amanda , Wainwright Brandon J. , Olson James M.
Published: April 2023

Legends describing the supplementary figures
Supplementary Figure S1 from A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Salvucci Manuela , Würstle Maximilian L. , Morgan Clare , Curry Sarah , Cremona Mattia , Lindner Andreas U. , Bacon Orna , Resler Alexa J. , Murphy Áine C. , O'Byrne Robert , Flanagan Lorna , Dasgupta Sonali , Rice Nadege , Pilati Camilla , Zink Elisabeth , Schöller Lisa M. , Toomey Sinead , Lawler Mark , Johnston Patrick G. , Wilson Richard , Camilleri-Broët Sophie , Salto-Tellez Manuel , McNamara Deborah A. , Kay Elaine W. , Laurent-Puig Pierre , Van Schaeybroeck Sandra , Hennessy Bryan T. , Longley Daniel B. , Rehm Markus , Prehn Jochen H.M.
Published: April 2023

Kaplan-Meier estimates for disease-free and overall survival for n=120 stage III patients of the discovery cohort. Patients were grouped based on the protein expression of Procaspase-9, XIAP, SMAC and Procaspase-3. Median expression was used as cut-off value.
Figure S2 from Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models
Authors: Cook Sangar Michelle L. , Genovesi Laura A. , Nakamoto Madison W. , Davis Melissa J. , Knobluagh Sue E. , Ji Pengxiang , Millar Amanda , Wainwright Brandon J. , Olson James M.
Published: April 2023

Figure S2 shows the investigation of BBB integrity in intracranial Med-211FH tumors using MRI.
Supplementary Tables 1-4 from PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients
Authors: Tobin Nicholas P. , Lundberg Arian , Lindström Linda S. , Harrell J. Chuck , Foukakis Theodoros , Carlsson Lena , Einbeigi Zakaria , Linderholm Barbro K. , Loman Niklas , Malmberg Martin , Fernö Mårten , Czene Kamila , Perou Charles M. , Bergh Jonas , Hatschek Thomas
Published: April 2023

Supplementary Table 1. Primary tumour characteristics of patients included in the translational TEX trial Supplementary Table 2. Metastatic signature subtype split by primary tumour PR status and adjuvant therapy (N = 109) Supplementary Table 3. Long and short-term univariate Cox regression analysis for all signatures, post-relapse BCSS as clinical endpoint Supplementary Table 4. Long and short-term Likelihood ratios for all signatures in metastases from All, lymph nodes and other sites combined groups
Supplementary Figures 1-4 from PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients
Authors: Tobin Nicholas P. , Lundberg Arian , Lindström Linda S. , Harrell J. Chuck , Foukakis Theodoros , Carlsson Lena , Einbeigi Zakaria , Linderholm Barbro K. , Loman Niklas , Malmberg Martin , Fernö Mårten , Czene Kamila , Perou Charles M. , Bergh Jonas , Hatschek Thomas
Published: April 2023

Supplementary Figure 1 CONSORT diagram, TEX cohort Supplementary Figure 2 Long term post-relapse BCSS for gene expression signatures Supplementary Figure 3 Short term post-relapse BCSS for gene expression signatures Supplementary Figure 4 Long and short term post-relapse BCSS Kaplan-Meier curves for PAM50 at specific metastatic sites